Vaxcyte CFO Sells Shares for Tax Obligations Amid Strong Share Performance and High Cash Reserves
Andrew Guggenhime, President and CFO of Vaxcyte (PCVX), recently disposed of 2,705 shares to satisfy tax obligations following the vesting of restricted stock units. The transaction was not a discretionary sale but an automatic transfer directly to the company upon vesting. Despite reporting a $605 million loss over six months and no revenue, Vaxcyte holds significant cash reserves—$2.51 billion as of June 30—and has seen its share price rise by 95% in one year. The company is focused on developing next-generation vaccines like VAX-24 for bacterial diseases. Guggenhime retains a substantial stake, holding approximately $10.1 million worth of shares directly and indirectly through an entity. His comments suggest confidence that the current financial position supports ongoing clinical development and commercial readiness.
Tickers: $PCVX